Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-Mosunetuzumab Antibody (9L411) is a Rabbit antibody targeting Mosunetuzumab. Anti-Mosunetuzumab Antibody (9L411) can be used in ELISA, Sandwich ELISA, Competitive ELISA.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 40 μg | $609 | 7-10 days | 7-10 days |
| Description | Anti-Mosunetuzumab Antibody (9L411) is a Rabbit antibody targeting Mosunetuzumab. Anti-Mosunetuzumab Antibody (9L411) can be used in ELISA, Sandwich ELISA, Competitive ELISA. |
| Synonyms | RO7030816, RO 7187797, RG 7828, RG 6160, Mosunetuzumab-axgb, Lunsumio, Cevostamab, BTCT-4465A, BFCR 4350A, Anti-FCRH5/CD3 BiTE |
| Ig Type | IgG, κ |
| Clone | 9L411 |
| Specificity | Mosunetuzumab and Cevostamab |
| Application | |
| Recommended Dose | ELISA: 0.01-1 µg/ml; Sandwich ELISA: 0.4-2 μg/ml; Competitive ELISA: 1-10 μg/ml |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Purification | Protein A affinity column |
| Appearance | Lyophilized. Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Formulation | Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Research Background | Mosunetuzumab is an innovative bispecific antibody that has a structure that resembles a natural human antibody, with two 'Fab' regions. However, it differs from naturally-occurring antibodies as one 'Fab' region targets CD20 and the other targets CD3. By recognizing and binding to these two different targets, Mosunetuzumab is able to redirect the cytotoxic activity of T-cells towards cancerous B-cells. This unique mechanism of action holds great potential for enhancing the effectiveness of cancer treatment. Cevostamab (BFCR4350A) is an innovative bispecific antibody, designed to engage T-cells and myeloma cells by targeting FcRH5 and CD3 receptors, respectively. Cevostamab possesses a unique structure with two 'Fab' regions, with one specifically targeting FcRH5 and the other targeting CD3. This dual targeting mechanism activates the patient's own T-cells and redirects them to eliminate myeloma cells expressing FcRH5 by releasing cytotoxic proteins. |
| Conjucates | Unconjugated |
| Immunogen | Mosunetuzumab |
| Stability & Storage | The lyophilized product store at -20°C or -80°C for 12 months. The reconstituted antibody can be stored at 2°C-8°C for 2-3 weeks or at -20°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.